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ABSTRACT: Hepatic encephalopathy (HE) is a multifactorial syndrome in which the function
of the central nervous system is impaired due to the metabolic consequences of liver disease. The
two main components of liver pathology which lead to HE are the decrease in the number of
functioning hepatocytes and the vascular rearrangement causing blood from the portal vein to bypass
the liver. The symptoms of HE range from mild cognitive impairment to deep coma. Some degree of
neuronal loss may be found in HE patients as a consequence of chronic cirrhosis and, in advanced
HE, of brain edema; however, most of the HE syndrome is reversible with compensation of the liver
disease. The pathogenesis of HE is not fully understood and is likely to be multifactorial. The initial
theories implicated accumulation of neurotoxins leading to an impairment of neuronal function.
With better understanding of the physiology of neuroreceptors, abnormalities in several
neurotransmission systems have been put forward as potential causes of HE, such as a reported
increase in GABAergic neurotransmission. There is evidence that this enhancement is related to an
increase in the potentiation of GABAergic action by ligands to the benzodiazepine receptor (BZR),
which are known to be increased in liver disease. With this evidence in mind, therapy with the
benzodiazepine antagonist flumazenil has been attempted in HE, yielding clinical benefit in a variable
percentage of patients in recent studies.  However, there is still a lack of evidence to support a
causal relationship between increased levels of benzodiazepine agonist ligands and HE symptoms.
It is feasible to think that this relationship exists in some but not all HE patients.
UNITERMS: Hepatic Encephalopathy. Benzodiazepines. Receptores,GABA-A. Flumazenil.
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1. INTRODUCTION
The relationship between psychiatric symptoms
and liver impairment has been described in Hippocratic
texts. However, the mechanisms through which
liver disease impairs brain function are still poorly
understood. The neuropsychiatric syndrome resulting
from liver impairment is generically known as hepatic
encephalopathy (HE). This syndrome can be classified
into different degrees or stages of severity, which range
from mild cognitive impairment, detectable only by
specific neuropsychological tests, to coma (Table I).
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Liver impairment can also induce irreversible
neurological alterations, including astrocytosis, cortical
thinning, neuronal loss in the cerebellum and basal
ganglia, laminar necrosis, spinal cord demyelination
and brain edema and compression(1/6). However, the
term “hepatic encephalopathy” is generally used to
describe reversible neurological impairment, and
therefore does not include cases with severe degrees
of any of the complications mentioned earlier(7).
The main theories on the genesis of HE are
based upon evidence of the accumulation of toxic sub-
stances. With increasing degrees of liver damage,
many metabolic pathways become obstructed, result-
ing in the accumulation of numerous substances which
may present neurotoxic properties. The HE syndrome
appears to be the result of the concomitant action of
these different substances. However, it is important to
try to distinguish which toxins are responsible for the
symptoms in different stages of HE. This distinction
is crucial for the design of new and more effective
therapeutic approaches. The clinical treatments avail-
able for chronic HE so far are palliative; only liver
transplantation tackles the real cause of chronic HE,
which ultimately consists of a lack of functioning hepa-
tocytes. In acute episodes of chronic HE or primary
acute HE episodes (such as those produced by
acetaminophen overdose) it is important to prevent
the progression of HE symptoms and to reverse the
existing brain impairments as quickly as possible.
The emergency status of acute HE episodes is partly
due to the fact that the symptoms frequently progress
to coma states, which are sometimes accompanied by
different degrees of brain edema and neuronal
damage. So far, only one drug has been shown to re-
verse HE related coma in at least a subset of patients:
the benzodiazepine antagonist flumazenil.
The rationale for using flumazenil in HE was
built up from evidence suggesting the involvement of
the GABA-benzodiazepine receptor complex in this
syndrome. The first findings suggesting that an increase
in GABAergic transmission was involved in HE came
from the liver diseases section in the NIH laborato-
ries(8). After identifying this increase in GABAergic
transmission, the NIH group and other research centers
began to search for explanations of this change. From
the beginning, two hypothesis were proposed: changes
in GABA neurotransmission could be explained by
alterations of either the structure or the level of ligands
to the GABA receptor and its related modulatory sites
(see section on the benzodiazepine receptor). The latter
mechanism is consistent with the evidence indicating
that humoral changes precipitated by substances origi-
nated in the gut may contribute to HE(9). This article
aims to review recent evidence on the pathogenesis of
HE, focusing on the role of benzodiazepines and of
the benzodiazepine receptor (BZR) in this process.
Table I - Clinical stages of hepatic encephalopathy
Stage Mental state Motor alterations
Pre-clinical Slowed analytical ability, increase in p300
latency
No change
I Mild confusion, impaired atention, sleep
inversion, mood changes (euphoria,
depression, irritability)
Tremor, incoordination, problems in
handwriting
II Amnesia for past events, drowsiness, lethargy,
inapropriate behaviour, intermittent
disorientation.  EEG shows high-amplitude,
low-frequency waves
Hypoactive reflexes, asterixis, ataxia, apraxia,
dysartria, paratonia
III Inability to perform analytical tasks,
disorientation, slurred speech, rage
Rigidity, hyperactive reflexes, nistagmus,
Babinski’s sign
IV Coma No response to painful stimuli, dilated pupils,
opisthotonus
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2. HEPATIC ENCEPHALOPATHY
HE is a multifactorial syndrome characterized
by depression of the central nervous system. The
symptoms are progressive and, in more severe cases,
impaired consciousness and coma may occur(10). HE
appears to be a result of both vascular and parenchy-
mal mechanisms. The vascular causes include a series
of pathological conditions in which toxic metabolites
accumulate in the systemic circulation due to vascular
bypass of the liver. Congenital portocaval shunts are
an example of “pure” vascular disease. The paren-
chymal causes of HE include the conditions in which
the blood supply to the liver is normal but the pop-
ulation of active hepatocytes is decreased. An example
of ‘pure’ parenchymal HE is fulminant hepatic failure
due to acetaminophen overdose. Most patients with
HE have some degree of both parenchymal insufi-
ciency and vascular rearrangement, lying between the
pure vascular and pure parenchymal extremes.
HE usually presents itself as a complication of
chronic hepatocellular disease, which is a common
consequence of alcoholic cirrhosis and chronic hepa-
titis. Precipitants of acute hepatocellular failure in-
clude acute viral hepatitis and drug overdose(11). Com-
mon precipitants of HE in a patient with cirrhosis in-
clude an intestinal nitrogen load in the form of in-
creased protein intake (meat, eggs and other protein-
rich foods), constipation and gastrointestinal bleed-
ing (usually from esophageal varices). Other precipi-
tants include infections, diarrhea, vomiting, hypoxia,
anemia, hypotension, hypoglicemia, dehydration,
electrolyte and/or acid-base disturbances and surgi-
cal procedures. The administration of sedative drugs
such as benzodiazepines, barbiturates and morphine
can also precipitate HE. When such precipitant fac-
tors trigger an HE episode, therapy is usually directed
to the treatment of these precipitants. However, HE
may present as a chronic condition, without a clear
precipitant factor. Chronic HE is a milder, more per-
sistent variant of the syndrome, occurring in patients
with parenchymal liver disease and some degree of
portal-systemic shunting.
2.1. Symptomatology
The earliest symptoms of HE are usually not
detectable by conventional clinical assessment but
may be apparent to family members or friends(10).
These symptoms include personality changes
reflecting forebrain dysfunction, such as childishness,
euphoria, irritability and apathy. A general decrease
in the speed of verbal and motor responses may also
occur, leading to a reduction of spontaneous move-
ments, fixed stare, dysphasia and perseveration in later
stages. Another common manifestation in early stages
is hypersomnia, which may progress to an inversion
of sleep rhythm. Intellectual deterioration may also
appear, and may be detected by psychological tests of
orientation to time, space and self; episodic memory;
subtraction of serial seven’s; handwriting and drawing;
trail-making and spatial recognition(12/14).
In more advanced cases, physical examination
signs of HE may emerge. A very typical sign of HE is
asterixis (liver flap or liver tremor). Asterixis is a result
of impaired reticular processing of proprioceptive
information from the metacarpophalangeal and wrist
joints. It is elicited by wrist dorsiflexion when the arm
is extended: the hand falls forward within 30 seconds,
with subsequent recovery of posture. Asterixis differs
from tremor because it is intermittent, of lower fre-
quency and bilaterally asynchronous(15,16). Others signs
which may develop in HE include hyperreflexia,
muscular rigidity and ankle clonus, fasciculations,
ataxic gait, decerebrate postures, bizarre facial ex-
pressions, Babinski’s sign, seizures and coma.
Patients with chronic liver disease who do not
present with overt symptoms of HE but show some
degree of impairment in psychological tests are
grouped into the category of subclinical HE(11).
Subclinical HE is best detected using neuropsycho-
logical tests(17,18,19). More recently, auditory evoked
potentials have been proposed as an useful tool to
detect HE in its early stages(20,21). Conventional treat-
ment of liver failure (lactulose, dietary restrictions)
may reverse the cognitive impairments of subclinical
HE(22,23,24) and the intravenous injection of flumaze-
nil can improve reaction time(25) and performance in
auditory evoked potentials testing(26), although these
results have been contested in later studies(27). Chronic
alcoholism per se also appears to induce deficits in
these tests, an effect which might also be related to
benzodiazepine activity(28,29).
2.2 Neuropathology
Cerebral atrophy has been reported in brain
scans of cirrhotic patients with chronic recurrent
HE(30,31). Some of these changes might be attribut-
able to the direct effects of alcohol; however, studies
with nonalcoholic chronic liver patients without overt
HE also indicate the presence of cerebral edema and
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cortical atrophy(32,33). These morphological changes
correlate with scores in both neuropsychological and
liver function tests. The findings from these studies
strongly suggest that liver impairment may lead to
cortical atrophy. However, the exact mechanisms
through which liver dysfunction produces neuronal
loss are still unknown. These morphological changes
are possibly involved in the genesis of some HE symp-
toms which are not reversible by clinical treatment or
liver transplantation(33,34). However, neuronal loss cer-
tainly cannot account for all symptoms of the syn-
drome: most deficits on cognitive performance are
reversible with liver transplantation(35) and subclinical
HE can be reversed with clinical treatment(23). It is
likely that the metabolic changes which produce HE
induce some degree of neurotoxicity, which may even-
tually cause neuronal loss in the long run.
The histological examination of the brain of
chronic cirrhotic patients frequently shows Alzheimer
type II astrocytosis in the cortex, putamen, globus
pallidus and cerebellum(36). Another finding in these
patients is an increase of peripheral-type BZRs (37,38,39).
As the peripheral BZR is associated with non-neuronal
brain constituents, the increase in peripheral BZRs is
thought to be a consequence of glial proliferation. No
structural changes in individual neurons have been
found in HE using electron microscope techniques(40),
but alterations in retinal glia cells, including vacu-
olization and mitochondrial swelling, have been
recently described (41).
2.3. Pathogenesis
The main etiological factor in HE seems to be
the accumulation of neurotoxic substances in the sys-
temic circulation(42). In normal circumstances, these
neurotoxic compounds are absorbed from the gut and
cleared from the systemic circulation by the liver.
When liver function is seriously impaired, these com-
pounds bypass the liver, gain direct access to the cir-
culation and, once they cross the blood-brain barrier,
may accumulate in the central nervous system. There
is evidence that toxins can impair neuronal function
in HE through several distinct mechanisms, including
depression of neuronal electric activity by oc-cupation
of brain neuroreceptors(8); inhibition of ionic
pumps(43,44) and inhibition of neuronal oxidative me-
tabolism(45). Most of the neurotoxic substances accu-
mulated in HE are thought to be metabolites produced
by enteric bacteria, a belief reinforced by the effec-
tiveness of non-absorbable antibiotics in the treatment
of chronic HE(46). Elevated concentrations of several
potentially toxic substances have been reported in HE.
These findings led to the postulation of several com-
peting theories about the genesis of HE symptoms,
none of which have been conclusively proved or dis-
proved so far. The main hypothesis are summarized
in Table II. Given the wide range of metabolic abnor-
malities and different symptoms in HE it is very likely
that the etiology of the syndrome is multifactorial (47,48).
2.3.1. Increased ammonia levels
The hypothesis that increased ammonia levels
resulting from impaired hepatic clearance might result
in HE is the oldest theory postulating metabolic
changes as the cause of HE. Ammonia is clearly
neurotoxic and evidence gathered in the early fifties
suggested that HE could result in part from increased
levels of this substance(49,50). The gastrointestinal tract
is a major source of ammonia, where it is generated
by the degradation of amines, amino acids and urea
by enteric bacteria(51,52). In liver failure, the ammonia
produced in the gut bypasses the liver, and higher
amounts of it reach the systemic circulation. Liver
impairment also reduces the conversion of ammonia
and glutamine into urea, resulting in further accu-
mulation of ammonia in the blood.
Several studies have shown that increased lev-
els of ammonia deactivate the ionic pump that actively
transports chloride out of the cell(43,53), leading to a
decrease in post-synaptic inhibition. These changes
have been demonstrated in the cerebral cortex, thala-
mus, brainstem and spinal cord in HE(43,54,55,56). The
resulting increase in neuronal excitation may lead to
hyperreflexia and seizures(57). Further elevations of
ammonia levels impair the formation of a post-syn-
aptic potential, producing pre-synaptic blockade and
overall depression of the central nervous system(58).
Hyperammonemia also induces several detrimental
metabolic changes in the Na+/K+-ATPase activity, the
t icarboxylic acid cycle, the malate/aspartate shuttle
and the glycolysis pathway(59/63).
Treatment with oral L-ornithine-L-aspartate,
which improves ammonia detoxification, has recently
been shown to significantly enhance cognition and
scores on the Portosystemic Encephalopathy (PSE)
Index(64), a clinical measure of severity in patients with
chronic HE(40). A correlation between chronic hepatic
encephalopathy and gastric colonization by urease-
producing Helicobacter pylori has also been shown,
and eradication of this microorganism appears to
improve symptomatology in colonized patients(65). On
the other hand, the finding that plasmatic levels of
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Table II - Hypothesises for the pathogenesis of hepatic encephalopathy
Hypothesis Evidence in favour of Evidence against
Ammonia - Clearly neurotoxic.
- Abundantly produced by gut bacteria.
- Accumulation promoted by liver failure.
- Treatment with L-ornithine-L-aspartate
improves ammonia detoxification and
HE symptoms.
- Correlation between H. pylori infection
and HE.
- Induces upregulation of BZRs and
GABAergic enhancement.
- Plasma levels do not correlate with the
severity of HE.
- Removal by hemodialysis does not
improve HE symptoms.
- Intoxication not known to produce
personality or sleep pattern changes.
Aromatic amino acids - Increased levels found in HE patients.
- Levels correlate with HE severity.
- May cause synthesis of false
neurotransmitter and alter
catecholaminergic transmission.
- Studies correlating levels of false
neurotransmitters and  HE are
controversial.
Mercaptans - Clearly neurotoxic.
- Produced by gut bacteria.
- Levels do not correlate with HE
severity.
- Controversies over detection methods.
Short and medium-chain
fatty acids
- Known to cause reversible coma.
- Increased levels found in patients with
chronic liver disease.
- No conclusive evidence of increased
levels in HE.
Phenols - Neurotoxic and hepatotoxic.
- Increased levels found in HE.
-  Levels found in HE are at least 4 times




- May be increased by toxins (ammonia,
mercaptans, phenols)
- Evidence for permeability increases in
fulminant hepatic failure.
- Little evidence of change in chronic
liver disease
- More likely to be a potentiating factor
for other toxins in HE.
Change in brain
monoamines
- Increased  levels of serotonin found in
HE models.
- Decreased levels of norepinephrine
found in HE models.
- No correlation between
neurotransmitter alterations and
neurological symptoms.
- Similar serotonin turnover in cirrhotics





- Evidence of increase in circulating BZR
ligands in animal models and patients
with HE.
- Increase in the brain levels of
benzodiazepines and in receptor density
and binding found in both animal
models and human patients.
- Positive correlation between HE
symptoms and BZR ligand levels.
- Treatment with flumazenil shows
efficacy in a variable percentage of
patients.
- Evidence for involvement of non-
benzodiazepine ligands to the BZR may
explain detection controversies.
- Increased levels of  benzodiazepines
found in a minority of patients.
- Levels seem to correlate more strongly
with the severity of liver disease than
with that of HE.
- Treatment with flumazenil shows
efficacy in a minority of patients.
- Possibility of a non-specific effect of
flumazenil cannot be ruled out.
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ammonia do not correlate with the severity of HE puts
the importance of ammonia in HE etiology in doubt(66).
Another evidence against a central role of ammonia
in HE is that hemodialysis, despite significantly
reducing ammonia levels, yields improvements in less
than 50 % of HE patients and may actually worsen
neurological symptoms in some cases(67). Another
argument against the ammonia hypothesis is that
ammonia intoxication does not produce the changes
in personality or sleep pattern commonly found in the
early stages of HE. However, ammonia also induces
changes in neurotransmitters such as GABA and can
enhance benzodiazepine activity through upregulation
of BZRs(68,69,70), which could account for these
alterations.
2.3.2. Changes in amino acid metabolism
It has been proposed that changes in amino acid
metabolism may also contribute to the HE syndrome.
There is evidence that the levels of aromatic amino
acids (tyrosine, phenilalanine and tryptophan) are in-
creased in patients with HE and correlate with the
severity of neurological impairment and with ammo-
nia levels in animal models of liver failure(71). Some
aromatic amino acids, particularly tryptophan, may
be directly neurotoxic(48,72,73). Moreover, they can also
impair the synthesis of catecholamines(74,75) and serve
as precursors to the synthesis of false neurotransmit-
ters such as octopamine and phenilethanolamine(11,76).
These false neurotransmitters can displace dopamine
and noradrenaline from synaptic vesicles, increasing
their degradation rate(77). Apart from depleting the
pool of monoamines, false neurotransmitters can also
suppress their synthesis by inhibiting the activity of
tyrosine hydroxylase and dopamine β-hydroxylase(78)
and act as partial agonists at the catecholamine re-
ceptors(79,80). Some studies have suggested a positive
correlation between octopamine levels in urine and
plasma and the severity of HE(81,82). However, other
studies came to directly opposite conclusions: the level
of octopamine in the brain of patients who died with
HE was found to be lower than that in patients who
died without liver disease(83). This leads us to believe
that, although abnormalities in the amino acid me-
tabolism may happen in HE, their role in the genesis
of the syndrome is not clear.
2.3.3. Other neurotoxins
Substances such as mercaptans, fatty acids and
phenols have also been implicated in HE. They can
be neurotoxic at certain levels and are potentially
accumulated in HE. There is no consistent evidence,
however, that any of these substances alone is capable
of producing the HE syndrome. Still, their neurotoxic
action may be mutually potentiated by the coexistence
of more than one toxin at the same time(84). This
might be a consequence of the ability of all of these
substances to reduce the activity of the Na+/K+
ATPase, which may lead to brain edema and
dysfunction(85).
Mercaptans such as methanethiol and dimeth-
yldisulfide were first isolated from a HE patient in
1955(86). These compounds are apparently formed
as a result of gut bacteria metabolism(84), and can in-
duce coma and convulsions by several mechanisms,
including suppression of Na+/K+ ATPase activity(84).
Their role in HE started to be questioned after the
finding that the method initially used to isolate mer-
captans could also synthesize them(87). Moreover, mer-
captan concentration also failed to correlate with the
degree of HE(88).
Short and medium chain fatty acids can also
cause reversible coma(84,89). Since increased levels
of free fatty acids have been described in patients
with chronic liver disease(90), these compounds too
have been implicated in HE. However, there is no
conclusive evidence of increased levels of fatty acids
in patients who develop HE(91).
Finally, phenols are metabolites of tyrosine and
phenylalanine which have been shown to be increased
in HE, probably as a consequence of the increase in
these aromatic amino acids(84,92), as discussed above.
These substances are both neurotoxic and hepatotoxic
and may induce coma or potentiate the ability of other
compounds to do so(93). However, the fact that the
levels of phenols detected in HE are at least 4 times
lower than the levels found to be neurotoxic in animal
models weakens this hypothesis(93,94).
2.3.4. Permeability of the blood-brain barrier
Apart from abnormal levels of toxic substances,
changes in the blood-brain barrier (BBB) have also
been put forward as a possible contributing factor in
HE. Some substances that accumulate in liver fail-
ure, such as ammonia, methyl octanoate, mercaptans,
phenol or dehydrocholate(95,96) may increase the
permeability of the BBB through several different
mechanisms. These mechanisms include a deleteri-
ous action on enzymes involved in the regulation of
transcapilar blood flow, changes in the function of
glial transporter systems and an increase in membrane
fluidity (97). There is evidence that the permeability of
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the BBB is increased for polar molecules (such as
amino-acids) in HE (98); on the other hand, other
studies suggest that the increase in BBB permeability
is nonspecific, including both polar and apolar
substances(98,99). It should be emphasized that the
findings suggesting increased permeability of the BBB
are more convincing regarding cases of fulminant
hepatic failure, as there is little evidence of BBB
changes in patients with chronic liver disease. Still, it
is possible that some degree of increased permeabil-
ity is present in these patients, which could theoreti-
cally potentiate the action of toxins in HE.
2.3.5. Changes in neurotransmission
Finally, changes in several neurotransmitter
systems have been implicated in HE. Because of the
impairment in amino acid metabolism induced by liver
failure, the most investigated systems have been the
amino acid and biogenic amine systems. Elevations
in the levels of serotonin (5-HT) in the brain were
postulated to contribute to the manifestations of
HE(100). However, 5-HT turnover has been reported
to be similar in cirrhotics with and without HE (101).
Moreover, no correlation between alterations in 5-HT
brain metabolism and neurological status has been
demonstrated(102). On the other hand, the levels of
norepinephrine (NE) have been reported to be
decreased in animal models of HE(103). However, it is
not clear that the depletion of NE in the brain is
causally related to the symptoms of HE(11). A decrease
in the excitatory activity of glutamate and aspartate
has also been put forward as a contributing factor to
HE symptoms(104). To this date, however, no firm
evidence supporting this hypothesis was reported.
Moreover, evidence of a compensatory increase in
aspartate neurotransmission has been found in HE(11).
More recently, the GABAergic system has been
implicated in HE. Evidence for this hypothesis will
be discussed in the next section.
3. HEPATIC ENCEPHALOPATHY AND THE
BENZODIAZEPINE RECEPTOR
3.1. Introduction
The involvement of the GABAA receptor in HE
was first hypothesized by Schafer & Jones(8). The
rationale behind this supposition was that the general
depression of the central nervous system found in HE
was compatible with a hyperactivity of the GABAergic
system. Evidence obtained from animal models of HE
upported this theory, as different groups found that
GABA agonists such as barbiturates, benzodiazepines
and muscimol potentiated HE symptoms(105,106), while
the administration of the GABA antagonist bicuculline
was found to improve neurophysiological changes and
behavioural symptoms of HE(106).
The initial studies implicating GABAergic neu-
rotransmission in HE did not provide a specific mecha-
nism for this change. An increase in GABAergic
neurotransmission could result from several factors,
ncluding higher GABA concentrations, increased
GABA receptor density, increased receptor affinity
or a combination of these factors. These possibilities
have been extensively investigated, but no firm con-
clusion has been reached so far. Initially, increased
r ceptor density was observed in animal models of
HE(107,108). Other studies failed to confirm these
findings, reporting no changes in receptor density or
affinity(109,110,111). An increase in blood concentrations
of GABA was also found in HE(112,113,114) but there
is no evidence that it would cross the blood-brain
barrier in sufficient amounts to produce a significant
effect(98,115).
3.2. The benzodiazepine receptor and hepatic
encephalopathy
Another possible mechanism of enhancement
of GABAergic neurotransmission relates to changes
in the benzodiazepine receptor (BZR) or in its ligands.
The BZR is part of the GABAA receptor complex
(Figure 1) and potentiates GABAergic inhibition
when it is activated. An increase in the density of
BZRs has been reported in animal models(108,116,117)
and in HE patients(118). These changes were contested
by subsequent studies reporting no change in these
receptors in HE, both in animal models(109) and in hu-
mans(119,120,121). Changes in the levels of ligands to the
BZR have also been reported in HE(122,123). This find-
ing led to the hypothesis that the cause for increased
GABAergic tonus in HE might be an increase in the
level of benzodiazepine-like ligands.
The possibility of having benzodiazepine-like
substances circulating and producing some of the
symptoms of HE prompted a great deal of research.
Initially, these substances were isolated from body flu-
ids of patients with HE and identified as benzodiaz-
epines and benzodiazepine agonists. Upon these find-
ings, treatment with the benzodiazepine antagonist
flumazenil was attempted in HE patients and  improve-
ments were found in some cases. Larger studies were
carried out trying to correlate the level of circulating
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benzodiazepines and the severity of liver disease and
HE. A positive correlation was found, and currently
the debate is on whether this correlation implicates in
a causal relationship(125). However, the implication of
benzodiazepines in HE has also been criticized. The
grounds for criticism stem from studies reporting that
increased levels of benzodiazepines are neither re-
quired nor sufficient to induce HE(126). Moreover, ben-
zodiazepine ligands seem to accumulate in severe liver
disease independently of the presence of HE, and their
levels are similar to those commonly found in exog-
enous benzodiazepine consumers(127). Double-blind,
placebo-controlled studies with flumazenil have been
carried out to elucidate the role of BZR ligands in
HE(128/131), but the answers are still unclear. Data in
favour and against the involvement of “endogenous
benzodiazepines” in HE will be summarized below.
3.2.1. Pre-clinical evidence
Increases in the levels of endogenous ligands
to the BZR have been demonstrated in a wide range
of experiments in animal models and humans. When
HE was induced in animals, the brain concentrations
of benzodiazepines were shown to be elevated(123). As
these animals had never been exposed to exogenous
benzodiazepines, this increase appears to be due to a
process inherent to HE. More recent experiments show
that gut bacteria such as Acinetobacter Iwoffii may
provide precursors of benzodiazepine ligands(132).
Benzodiazepine concentrations have been shown to
be increased in the cerebrospinal fluid(133,134,135) and
in post-mortem brain samples(136) of patients with HE.
BZR binding in the brain of patients with recurrent
HE has also been shown to be increased in positron
emission tomography (PET) studies(137). However, one
Figure 1: The GABAA receptor complex and its modulatory sites (for benzodiazepines, ethanol, barbiturates and
other substances). The benzodiazepine receptor is formed by the junction of the α  andγ  subunits; this receptor is the
site of action for both benzodiazepine agonists and flumazenil. Adapted from McKernan et al, 1996 (124).
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must consider that liver cirrhosis per se can also in-
duce changes in BZR binding(138).
However, despite the evidence for an increase
in BZR activity in the brain, elevated plasmatic lev-
els of benzodiazepines are found in a minority of HE
patients(128,131), even in those who respond to fluma-
zenil (see next section). Moreover, eventual increases
can frequently be traced to consumption of commer-
cial benzodiazepines(128). This prompted a search for
non-benzodiazepine ligands to the BZR, such as those
isolated in the neurological syndrome known as
idiopathic recurrent stupor(139,140) and later identified
as endozepine-2 and -4(141). An experiment with 25
patients in different HE stages(142) showed that most
of the benzodiazepine activity in these patients was
due to chemically unidentified benzodiazepine ago-
nists, and that total benzodiazepine-like activity cor-
related more strongly with the clinical stage of HE
than did the levels of conventional benzodiazepines
(diazepam and n-desmethyldiazepam).
The increase in benzodiazepine-like compounds
has been subsequently reported in patients with both
acute hepatic failure(143) and chronic cirrhosis(126).
However, this increase has been inconsistent, suggest-
ing that the occurrence of HE is also dependent on
several other factors. A study in which HE was in-
duced in 17 rats found a significant increase of  “en-
dogenous benzodiazepines” in only one animal(125),
suggesting that increased BZR ligand activity might
be due to increased residence time of exogenous ben-
zodiazepines in the body and that this increase would
be neither necessary nor sufficient to induce HE(125).
However the methodology employed in the experi-
ment did not include the extraction and purification
protocols applied by most of the authors in the field(144).
More solid criticism is provided by a recent
study by AVALLONE et al.(127) comparing the levels
of benzodiazepine-like ligands in cirrhotic patients
with and without overt HE. Although these levels were
shown to be significantly higher in patients with overt
HE as opposed to control cirrhotics, they correlated
more clearly with the degree of liver impairment ac-
cording to the Child-Pugh classification than with the
stage of HE itself. Therefore, the increased levels of
“endogenous benzodiazepines” in HE might be a mere
consequence of more severe liver disease with no
causal relationship to the syndrome, a hypothesis re-
inforced by the fact that these levels are similar to
those found in commercial benzodiazepine users
without any evidence of neurological impairment(127).
Increased levels of “endogenous benzodiazepines”
might also be related to a decrease in renal function(145),
which is a common complication of severe liver dis-
ease. Despite these remarks, however, the clinical evi-
dence showing the efficacy of flumazenil in the treat-
ment of HE suggests that endogenous benzodiazepines
are involved in the pathogenesis of this process in at
least some patients, as will be discussed below.
3.2.2. Clinical evidence - a role for flumazenil ?
The first report implicating “endogenous
benzodiazepines” in HE was an anedoctal report
of improvement in hepatic coma in a patient after a
1 minute injection of 0.5 mg of flumazenil by
SCOLLO-LAVIZZARI & STEIMAN (146). In this case
report, the patient improved dramatically: she opened
her eyes, reacted to verbal commands and moved
spontaneously and reacting to pain. This improvement
lasted for approximately one hour, with the patient
relapsing into coma afterwards. Since flumazenil does
not appear to present intrinsic inverse agonist activ-
ity in HE - that is, it cannot alter GABAergic trans-
mission on its own, although partial agonism has been
reported in animal models(147) - the reversal of he-
patic coma was interpreted as a possible antagonism
of endogenous benzodiazepine-like ligands. Several
case reports and uncontrolled trials showing positive
results followed this initial description. A review of
hese initial studies(11) showed that 69% of the pa-
tients improved after flumazenil. The clinical response
had the same pattern referred in the case reports, with
the improvement being quick and short-lived(148/156).
In most of these studies, however, intake of
synthetic benzodiazepines by the patients could not
be ruled out with certainty. Therefore, it is possible
that the response to flumazenil injection was just a
consequence of the temporary displacement of syn-
thetic benzodiazepines from the BZR. Moreover, in
some of the studies, the effect of flumazenil was re-
ported hours after the injection, which is not consis-
tent with the short half-life of the drug. These incon-
sistencies brought on the need of well-controlled clini-
cal trials to shed more light on the real efficacy and
mechanism of action of flumazenil.
 The first randomized clinical trial reported in
the literature was a double-blind, placebo-controlled,
crossover study by POMIER-LAYRARGUES et
al.(128), which showed improvement in 6 of 13 coma-
tose (grade IV HE) patients (46%) treated with intra-
venous injection of flumazenil, against none of 11 in
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the placebo group. However, commercial benzodiaz-
epines were detected in the blood of two responders
and two nonresponders -  therefore, in two out of the
six patients which showed improvement after fluma-
zenil, the clinical effect might have been related to
antagonism of the previously used medication.
In a later trial by GROENEWEG et al.(129)
using alterations in the electroencephalogram (EEG)
as a measure of clinical improvement in 32 patients
with an HE grade of I-III, improvements after fluma-
zenil administration were limited to 29% of cases, as
opposed to 13% after placebo. The EEG improve-
ments correlated with the patients’ clinical response
in 3 out of 5 cases. Another trial analysing a similar
population of non-comatose patients, but using the
clinical PSE score as a measure of improvement was
undertaken by GYR et al.(130). The overall efficacy
of flumazenil remained at 25% (7 out of 28 patients
vs. none of 21 in the placebo group) - however, the
improvement was greater (43%) in patients with a
stage III PSE score, as opposed to only 14% of
patients with PSE stage II.
By far, however, the largest clinical trial of
flumazenil was the randomized, double-blind, multi-
center, placebo-controlled cross-over study recently
published by BARBARO et al.(131), comprising 527
patients analysed in the course of 5 years. In this study,
flumazenil brought improvement in the neurological
score of 17.5% of HE grade III patients and 14.7% of
grade IVa patients, while improvements in EEG
tracings were seen in 27.8% of grade III patients and
21.5% of grade IVa patients. However, if only the re-
sults of the initial treatment (before the groups were
crossed over) are considered, these numbers rise to
26.5% (grade III) and 23.3% (grade IVa) for the
neurological score and 38.6% (grade III) and 33.8%
(grade IVa) for EEG improvements, suggesting that
administration of flumazenil early in the course of
the illness warrants better results.
Although they failed to recognize it in their
analysis, Barbaro et al.’s data provides evidence that
patients with alcoholic cirrhosis respond to flumaze-
nil much more frequently than patients with posthep-
atitic cirrhosis (22.3% as opposed to 11.3%)(157). This
is in agreement with data showing increased BZR bind-
ing in these patients(29) and might be useful to identify
patients who might respond to flumazenil. This is very
relevant because, although it appears clear that flu-
mazenil is beneficial for a subset of patients with HE,
the opinions on whether its large-scale use is warranted
by this somewhat limited efficacy are still conflict-
ing(129,131), given the high cost of the therapy and other
factors. It is important, therefore, that one can iden-
tify consistent indicators of a positive response to flu-
mazenil to be able to direct therapy to these patients.
Another potential application of flumazenil is
in the long-term treatment of chronic HE when ad-
ministered orally(158). In an interesting case reported
by FERENCI et al.(159), a patient with refractory HE
(12 episodes of coma in 2 years) after extensive liver
resection had all signs of encephalopathy cleared for
14 months after twice a day oral administration of
flumazenil was instituted. To our knowledge, this kind
of approach has been repeated only once in a subse-
quent case report (160). Still, when one considers that
the benzodiazepine antagonist also shows effect in
reversing cognitive deficits in alcoholic cirrhotics(28),
the possibility of long-term treatment seems attrac-
tive. Specific studies should be carried out to deter-
mine its real usefulness in chronic HE.
4. CONCLUSION
When the efficacy of flumazenil in the clinical
trials mentioned above is considered, it appears that
BZR ligands should be involved in at least some cases
of HE. Still, we cannot rule out that the effect observed
with this drug might be due to a nonspecific excitation
of the nervous system, as is observed  in poisoning
and metabolic coma(161,162), or due to its intrinsic
agonist effects. However, the wide array of evidence
reporting increases in “endogenous benzodiazepines”
and BZR activity in HE favours the hypothesis that
the action of flumazenil is due to the antagonism of
these substances, and that they might indeed play a
role in the pathogenesis of HE.
Still, it appears clear that there is a very large
group of patients who do not respond to flumazenil
therapy; moreover, the detection of increased levels
of benzodiazepine-like ligands in HE patients is not
totally consistent and does not always correlate clearly
to the severity of the disease. Therefore, it appears
that the activation of the BZR is one of several
different mechanisms contributing to HE. This
reaffirms the concept that HE is a multifactorial
syndrome and emphasises the need of a wide thera-
peutic approach, in which benzodiazepine antagonists
might come to play a role. More studies are thus
necessary to determine which patients might benefit
from treatment with flumazenil and to establish
the true role of the BZR and its pharmacology in the
pathogenesis and therapeutics of HE.
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RESUMO: A encefalopatia hepática (EH) é uma síndrome multifatorial, na qual a função do
sistema nervoso central está alterada devido às conseqüências metabólicas da disfunção hepática.
Os dois principais componentes das doenças hepáticas que levam à EH são a diminuição no núme-
ro de hepatócitos funcionantes e o rearranjo vascular, que leva à diminuição na fração de sangue,
efetivamente detoxificado pelo fígado. Os sintomas da EH podem variar de déficits cognitivos leves
até o coma profundo. Algum grau de morte neuronal pode ser observado em pacientes com EH,
como conseqüência da cirrose hepática, ou, na EH avançada, da presença de edema cerebral. No
entanto, a maior parte da síndrome neurológica é reversível com a compensação da doença hepá-
tica. A etiologia da EH não é totalmente conhecida e trata-se, provavelmente, de um processo
multifatorial. Inicialmente, as teorias apontavam para o acúmulo de neurotoxinas que prejudicariam
a função neuronal. Mais recentemente, anormalidades em vários sistemas de neurotransmissão
foram propostos como causas potencias da EH como, por exemplo, o aumento observado na
neurotransmissão GABAérgica. Existe evidência de que este aumento esteja relacionado com o
aumento da potenciação GABAérgica por substâncias de ação similar aos benzodiazepínicos, as
quais se encontram aumentadas na EH. Com esta evidência em mente, foi tentada a terapia desta
síndrome com flumazenil, um antagonista benzodiazepínico, o qual tem mostrado eficácia clínica
em uma porcentagem variável de pacientes em estudos recentes. No entanto, ainda não há evidên-
cias conclusivas para sustentar uma relação causal entre o aumento de ligantes ao receptor de
benzodiazepínicos e os sintomas da EH. É possível que esta relação exista em alguns, mas não em
todos os pacientes com esta síndrome.
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